全文获取类型
收费全文 | 671205篇 |
免费 | 52098篇 |
国内免费 | 21023篇 |
专业分类
耳鼻咽喉 | 6760篇 |
儿科学 | 14431篇 |
妇产科学 | 9354篇 |
基础医学 | 89312篇 |
口腔科学 | 13298篇 |
临床医学 | 58852篇 |
内科学 | 104582篇 |
皮肤病学 | 10038篇 |
神经病学 | 45683篇 |
特种医学 | 24754篇 |
外国民族医学 | 118篇 |
外科学 | 69144篇 |
综合类 | 82480篇 |
现状与发展 | 80篇 |
一般理论 | 14篇 |
预防医学 | 41191篇 |
眼科学 | 9842篇 |
药学 | 86023篇 |
201篇 | |
中国医学 | 27937篇 |
肿瘤学 | 50232篇 |
出版年
2024年 | 1043篇 |
2023年 | 9073篇 |
2022年 | 13813篇 |
2021年 | 30731篇 |
2020年 | 22476篇 |
2019年 | 25765篇 |
2018年 | 21604篇 |
2017年 | 22249篇 |
2016年 | 23659篇 |
2015年 | 26725篇 |
2014年 | 41131篇 |
2013年 | 45249篇 |
2012年 | 43246篇 |
2011年 | 44659篇 |
2010年 | 36574篇 |
2009年 | 36858篇 |
2008年 | 35905篇 |
2007年 | 35358篇 |
2006年 | 31651篇 |
2005年 | 25581篇 |
2004年 | 19277篇 |
2003年 | 16897篇 |
2002年 | 13317篇 |
2001年 | 11474篇 |
2000年 | 10041篇 |
1999年 | 8291篇 |
1998年 | 7576篇 |
1997年 | 7237篇 |
1996年 | 6589篇 |
1995年 | 6092篇 |
1994年 | 5692篇 |
1993年 | 4752篇 |
1992年 | 4438篇 |
1991年 | 4090篇 |
1990年 | 3682篇 |
1989年 | 3247篇 |
1988年 | 2996篇 |
1987年 | 2632篇 |
1986年 | 2410篇 |
1985年 | 4253篇 |
1984年 | 4266篇 |
1983年 | 2988篇 |
1982年 | 3288篇 |
1981年 | 2903篇 |
1980年 | 2570篇 |
1979年 | 2139篇 |
1978年 | 1590篇 |
1977年 | 1437篇 |
1976年 | 1320篇 |
1975年 | 903篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
目的 探讨滋肾育胎丸加减方预防抗磷脂抗体(ACA)阳性者不良妊娠结局的效果及机制研究。方法 选取2016年2月至2019年2月我院收治的89例ACA阳性,先兆性流产或有习惯性流产(RSA)史患者,将采用西医治疗的40例作为对照组,将采用西医联合滋肾育胎丸加减方治疗的49例作为观察组,比较两组中医证候疗效、中医证候积分、ACA-IgA、ACA-IgM、ACA-IgG、凝血指标[血小板聚集功能(PAF)、活化蛋白C(PC)、抗凝血酶(AT)、纤溶酶原激活抑制物-1(PAI-1)]、Th1/Th2细胞因子[干扰素γ(IFN-γ)、白介素-2(IL-2)、白介素-4(IL-4)、白介素-10(IL-10)]、妊娠结局、安全性。结果 治疗2周后检测ACA,观察组2例未降低,对照组11例未降低,观察组未降低患者占比低于对照组(P<0.05);观察组总有效率100.00%高于对照组85.00%(P<0.05);观察组治疗4周、7周后中医证候积分低于对照组(P<0.05);观察组治疗4周、7周后ACA-IgA、ACA-IgM、ACA-IgG低于对照组(P<0.05);观察组治疗4周、7周后PAF、PAI-1低于对照组,PC、AT高于对照组(P<0.05);观察组治疗4周、7周后IFN-γ、IL-2低于对照组,IL-4、IL-10高于对照组(P<0.05);观察组活产率95.92%高于对照组80.00%(P<0.05);组间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 动态监测ACA对滋肾育胎丸加减方精准应用具有指导意义,指导滋肾育胎丸加减方通过调理脏腑、气血、经络功能,改善先兆性流产或有RSA史患者临床症状及凝血因子指标,降低ACA水平,并可改善患者免疫耐受功能,提高胎儿活产率,且安全性高。 相似文献
53.
角膜移植为治疗角膜盲的主要手段,而角膜移植排斥则是决定角膜植片存活时间和病人术后视力的关键。角膜得益于其特殊的眼前节“免疫赦免”状态,使得角膜移植能够在众多器官移植中享有极低的排斥率,然而排斥反应发生的风险依然存在。当机体处于遗传物质异常的特殊状态时,宿主将通过宏观调控“免疫赦免”状态对植片的保护作用或受体对移植物排异产生的有害作用,延迟或促进角膜移植排斥反应的发生,进而影响移植物的存活时间和透明度。该文综述与角膜移植排斥相关的多种全身性遗传疾病,总结全身性遗传疾病对角膜移植排斥的影响,浅析其发生的病理生理学机制以及诊疗的特殊性。 相似文献
54.
55.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
56.
《The Journal for Nurse Practitioners》2022,18(2):245-247
Transient stress hyperglycemia in the setting of acute myocardial infarction is a frequent phenomenon. Its transient nature should not dissuade the clinician from management of elevated blood glucose in a patient after an ST-elevation myocardial infarction. This case presents an adult patient after an ST-elevation myocardial infarction with transient stress hyperglycemia and the evidence used to identify optimal pharmacologic management and secondary prevention. 相似文献
57.
58.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献
59.
《Pancreatology》2022,22(8):1175-1180
BackgroundHepatic steatosis has been described as a common finding in adults following total pancreatectomy with islet autotransplantation (TPIAT) but it is unknown if this occurs in children and adolescents.ObjectivesTo define the frequency of post-TPIAT hepatic steatosis in a sample of children and adolescents and to identify clinical predictors of incident steatosis post-TPIAT.MethodsIn this prospective study, consecutive participants at least 1-month post-TPIAT underwent a liver MRI with proton density fat fraction (PDFF) and blood draw at our pediatric academic medical center between April 2021 and January 2022. Comparison clinical pre-TPIAT liver MRI or ultrasound and insulin use and graft function data were extracted from the medical record. T-tests were used for the comparison of means across continuous variables between participants with and without post-TPIAT steatosis.ResultsA total of 20 participants (mean: 13 ± 4 years; 12 female) were evaluated. Mean liver PDFF at research MRI was 7.4 ± 6.2% (range: 2–25%). Seven participants (35%) had categorical hepatic steatosis (PDFF>5%) post-TPIAT, five of whom had pre-TPIAT steatosis, reflecting a 13% (2/15; 95% CI: 2–40%) incidence of post-TPIAT steatosis. Participant characteristics were not significantly different between subgroups with and without post-TPIAT steatosis. Mean PDFF at research MRI was not different between graft function subgroups (7.5% optimal/good vs. 7.3% marginal/failure; p = .96).ConclusionOur study shows a moderate prevalence but low incidence of hepatic steatosis in a small sample of children and adolescents post-TPIAT. This study raises questions about a causal relationship between TPIAT and hepatic steatosis. 相似文献
60.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献